45. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J, 2007, 30(4): 782-800.
[2]
46. Guinea J, Torres-Narbona M, Gijon P, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect, 2010, 16(7): 870-877.
[3]
47. Xu H, Li L, Huang WJ, et al. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China. Clin Microbiol Infect, 2012, 18(4): 403-408.
[4]
48. Chen QK, Jiang GN, Ding JA. Surgical treatment for pulmonary aspergilloma: a 35-year experience in the Chinese population. Interact Cardiovasc Thorac Surg, 2012, 15(1): 77-80.
[5]
1. Desai SR, Hedayati V, Patel K, et al. Chronic aspergillosis of the lungs: unravelling the terminology and radiology. Eur Radiol, 2015, 25(10): 3100-3107.
[6]
2. Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax, 2014, 70(3): 270-277.
[7]
3. Patterson KC, Strek ME. Diagnosis and treatment of pulmonary aspergillosis syndromes. Chest, 2014, 146(5): 1358-1368.
[8]
4. Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J, 2016, 47(1): 45-68.
[9]
5. Godet C, Philippe B, Laurent F, et al. Chronic pulmonary aspergillosis: an update on diagnosis and treatment. Respiration, 2014, 88(2): 162-174.
[10]
6. Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J, 2011, 37(4): 865-872.
[11]
7. Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ, 2011, 89(12): 864-872.
[12]
8. Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J, 2013, 41(3): 621-626.
[13]
9. Felton TW, Baxter C, Moore CB, et al. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis, 2010, 51(12): 1383-1391.
[14]
10. Nam HS, Jeon K, Um SW, et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis, 2010, 14(6): e479-e482.
[15]
11. Muldoon EG, Sharman A, Page I, et al. Aspergillus nodules; another presentation of chronic pulmonary aspergillosis. BMC Pulm Med, 2016, 16(1): 123.
[16]
12. Kang EY, Kim DH, Woo OH, et al. Pulmonary aspergillosis in immunocompetent hosts without underlying lesions of the lung: radiologic and pathologic findings. Am J Roentgenol, 2002, 178(6): 1395-1399.
[17]
13. Sagan D, Gozdziuk K. Surgery for pulmonary aspergilloma in immunocompetent patients: no benefit from adjuvant antifungal pharmacotherapy. Ann Thorac Surg, 2010, 89(5): 1603-1610.
[18]
14. Cadrane J, Philipp B, Hennequi C, et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis, 2012, 31(11): 3231-3239.
[19]
15. Nakamoto K, Takayanagi N, Kanauchi T, et al. Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis. Intern Med, 2013, 52(7): 727-734.
[20]
16. Jung SW, Kim MW, Cho SK, et al. A case of endobronchial aspergilloma associated with foreign body in immunocompetent patient without underlying lung disease. Tuberc Respir Dis (Seoul), 2013, 74(5): 231-234.
[21]
17. Sridhar V, Rajagopalan N, Shivaprasad C, et al. Acute community acquired Aspergillus pneumonia in a presumed immunocompetent host. BMJ Case Rep, 2012, 2012.
[22]
18. Ergene U, Akcali Z, Ozbalci D, et al. Disseminated aspergillosis due to Aspergillus niger in immunocompetent patient: a case report. Case Rep Infect Dis, 2013, 2013: 385190.
20. Russell K, Broadbridge C, Murray S, et al. Gardening can seriously damage your health. Lancet, 2008, 371(9629): 2056.
[25]
21. Jung N, Mronga S, Schroth S, et al. Gardening can induce pulmonary failure: Aspergillus ARDS in an immunocompetent patient, a case report. BMC Infect Dis, 2014, 14(1): 600.
[26]
22. Aspergilloma and residual tuberculous cavities--the results of a resurvey. Tubercle, 1970, 51(3): 227-245.
[27]
23. Sambatakou H, Pravica V, Hutchinson IV, et al. Cytokine profiling of pulmonary aspergillosis. Int J Immunogenet, 2006, 33(4): 297-302.
[28]
24. Kelleher P, Goodsall A, Mulgirigama A, et al. Interferon-gamma therapy in two patients with progressive chronic pulmonary aspergillosis. Eur Respir J, 2006, 27(6): 1307-1310.
[29]
25. Carvalho A, Pasqualotto AC, Pitzurra L, et al. Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis, 2008, 197(4): 618-621.
[30]
26. Vaid M, Kaur S, Sambatakou H, et al. Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. Clin Chem Lab Med, 2007, 45(2): 183-186.
[31]
27. He Q, Li H, Rui Y, et al. Pentraxin 3 gene polymorphisms and pulmonary aspergillosis in chronic obstructive pulmonary disease patients. Clin Infect Dis, 2018, 66(2): 261-267.
[32]
28. Chen JC, Chang YL, Luh SP, et al. Surgical treatment for pulmonary aspergilloma: a 28 year experience. Thorax, 1997, 52(9): 810-813.
[33]
29. Park CK, Jheon S. Results of surgical treatment for pulmonary aspergilloma. Eur J Cardiothorac Surg, 2002, 21(5): 918-23.
[34]
30. Babatasi G, Massetti M, Chapelier A, et al. Surgical treatment of pulmonary aspergilloma: current outcome. J Thorac Cardiovasc Surg, 2000, 119(5): 906-912.
[35]
31. Demir A, Gunluoglu MZ, Turna A, et al. Analysis of surgical treatment for pulmonary aspergilloma. Asian Cardiovasc Thorac Ann, 2006, 14(5): 407-411.
[36]
32. Lee JG, Lee CY, Park IK, et al. Pulmonary aspergilloma: analysis of prognosis in relation to symptoms and treatment. J Thorac Cardiovasc Surg, 2009, 138(4): 820-825.
[37]
33. Kohno S, Izumikawa K, Ogawa K, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect, 2010, 61(5): 410-418.
[38]
34. Jhun BW, Jeon K, Eom JS, et al. Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis. Med Mycol, 2013, 51(8): 811-817.
[39]
35. Denning DW, Riniotis K, Dobrashian R, et al. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis, 2003, 37 Suppl 3: S265-S280.
[40]
36. Sambatakou H, Dupont B, Lode H, et al. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med, 2006, 119(6): 527.e17-e24.
[41]
37. Ohba H, Miwa S, Shirai M, et al. Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med, 2012, 106(5): 724-729.
[42]
38. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med, 2007, 101(6): 1163-70.
[43]
39. Li AM, Sonnappa S, Lex C, et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management. Eur Respir J, 2005, 26(1): 8-14.
[44]
40. Tsang KW, Lam SK, Lam WK, et al. High seroprevalence of Helicobacter pylori in active bronchiectasis. Am J Respir Crit Care Med, 1998, 158(4): 1047-1051.
[45]
41. Guan WJ, Gao YH, Xu G, et al. Aetiology of bronchiectasis in Guangzhou, southern China. Respirology, 2015, 20(5): 739-748.
[46]
42. Camuset, J, Nunes, H, Dombret, MC, et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest, 2007, 131(5): 1435-1441.
[47]
43. Chawla K, Kosaraju K, Rayasam S, et al. Clinico-microbiological profile of chronic pulmonary aspergillosis from a tertiary care centre in southern India. J Clin Diagn Res, 2013, 7(12): 2712-2715.
[48]
44. Camara B, Reymond E, Saint-Raymond C, et al. Characteristics and outcomes of chronic pulmonary aspergillosis: a retrospective analysis of a tertiary hospital registry. Clin Respir J, 2015, 9(1): 65-73.
